Mu X - Search Results

1

Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.

Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, Zhou Q, Zhang S, Wang D, Shi H, Gao Y, Huang Y, Li G, Wang X, Cheng Y, Lou G, Gao Q, Wang L, Du X, Pan M, Mu X, Li L, Li M, Mu S, Kong B. Wu X, et al. Among authors: mu x, mu s. Clin Cancer Res. 2022 Feb 15;28(4):653-661. doi: 10.1158/1078-0432.CCR-21-1186. Clin Cancer Res. 2022. PMID: 34844979 Free PMC article. Clinical Trial.

2

Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.

Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L, Mu S, Zhang W, Li M. Xu B, et al. Among authors: mu x, mu s. Cancer Med. 2021 Jan;10(1):109-118. doi: 10.1002/cam4.3575. Epub 2020 Oct 31. Cancer Med. 2021. PMID: 33128299 Free PMC article. Clinical Trial.

3

Comparison of pulsed actinomycin D and 5-day actinomycin D as first-line chemotherapy for low-risk gestational trophoblastic neoplasia.

Mu X, Song L, Li Q, Yin R, Zhao X, Wang D. Mu X, et al. Int J Gynaecol Obstet. 2018 Nov;143(2):225-231. doi: 10.1002/ijgo.12629. Epub 2018 Aug 16. Int J Gynaecol Obstet. 2018. PMID: 30051913

4

Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: A case report.

Mu X, Yin R, Wang D, Song L, Ma Y, Zhao X, Li Q. Mu X, et al. Medicine (Baltimore). 2018 Sep;97(38):e12424. doi: 10.1097/MD.0000000000012424. Medicine (Baltimore). 2018. PMID: 30235719 Free PMC article.

5

Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity.

Mu X, Fang C, Zhou J, Xi Y, Zhang L, Wei Y, Yi T, Wu Y, Zhao X. Mu X, et al. J Cancer Res Clin Oncol. 2016 Jan;142(1):111-23. doi: 10.1007/s00432-015-2002-6. Epub 2015 Jul 3. J Cancer Res Clin Oncol. 2016. PMID: 26139353

6

Gene Polymorphisms of Toll-Like Receptor 9 -1486T/C and 2848G/A in Cervical Cancer Risk.

Mu X, Zhao J, Yuan X, Zhao X, Yao K, Liu Y, Zhao X. Mu X, et al. Int J Gynecol Cancer. 2015 Sep;25(7):1173-8. doi: 10.1097/IGC.0000000000000494. Int J Gynecol Cancer. 2015. PMID: 26270118

7

The association between HOTAIR polymorphisms and cancer susceptibility: an updated systemic review and meta-analysis.

Min L, Mu X, Tong A, Qian Y, Ling C, Yi T, Zhao X. Min L, et al. Among authors: mu x. Onco Targets Ther. 2018 Feb 14;11:791-800. doi: 10.2147/OTT.S151454. eCollection 2018. Onco Targets Ther. 2018. PMID: 29497311 Free PMC article.

8

The association of FOXP3 gene polymorphisms with cancer susceptibility: a comprehensive systemic review and meta-analysis.

Chen Y, Qi X, Bian C, Ling C, Yi T, Mu X, Zhao X. Chen Y, et al. Among authors: mu x. Biosci Rep. 2019 Mar 19;39(3):BSR20181809. doi: 10.1042/BSR20181809. Print 2019 Mar 29. Biosci Rep. 2019. PMID: 30782783 Free PMC article.

9

Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells.

Mu X, Sang Y, Fang C, Shao B, Yang L, Yao K, Zhao X, Gou J, Wei Y, Yi T, Wu Y, Zhao X. Mu X, et al. Int J Oncol. 2015 Nov;47(5):1901-11. doi: 10.3892/ijo.2015.3175. Epub 2015 Sep 21. Int J Oncol. 2015. PMID: 26398907

10

Antitumor immunity induced by VE-cadherin modified DC vaccine.

Zhou J, Xi Y, Mu X, Zhao R, Chen H, Zhang L, Wu Y, Li Q. Zhou J, et al. Among authors: mu x. Oncotarget. 2017 Jun 27;8(40):67369-67379. doi: 10.18632/oncotarget.18654. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978039 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,771 results

Search Page

Filters